Phase 3 results posted, week of October 19, 2026: 2 industry trials
Industry sponsors posted results for 2 Phase 3 trials on ClinicalTrials.gov so far in the week of October 19 to 25, 2026. Together the trials enrolled 405 participants; the largest, Protagonist Therapeutics' VERIFY trial, enrolled 293.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, October 25, 2026.
The trials
- Protagonist posts results of Phase 3 rusfertide study in polycythemia vera. Sponsor: Protagonist Therapeutics, Inc. Condition: Polycythemia Vera. Intervention: Rusfertide. Phase: Phase 3. Enrollment: 293 (actual). Results first posted October 19, 2026. Record: NCT05210790 (VERIFY).
- Janssen posts results of Phase 3 ustekinumab trial in pediatric ulcerative colitis. Sponsor: Janssen Research & Development, LLC. Condition: Colitis, Ulcerative. Intervention: Ustekinumab Dose Based on BSA and Body Weight. Phase: Phase 3. Enrollment: 112 (actual). Results first posted October 20, 2026. Record: NCT04630028 (UNIFI Jr).
By the numbers
- Trials: 2, from 2 lead sponsors.
- Participants: 405 in all across 2 trials; median 203 per trial.
- Largest: Protagonist Therapeutics' VERIFY trial, 293. Smallest: Janssen Research & Development's UNIFI Jr trial, 112.
- Phases as registered: 2 Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.